Everyone’s talking about semaglutide, tirzepatide, retatrutide — and they all basically work the same way, tweaking variations on one hormone system. Cagrilintide doesn’t. It’s the odd one out in the GLP-1 conversation, and that’s exactly why researchers are so interested in it: not because it’s a better version of the same drug, but because it isn’t playing the same game at all.
What Is Cagrilintide?
Cagrilintide (you’ll also see it called AM833 or NN9838 in older research) is a long-acting lab-made version of amylin, a hormone your pancreas releases alongside insulin every time you eat. Amylin’s actual job is to tell your brain “you’re full,” slow down digestion, and help keep blood sugar steady after a meal.
The problem with using natural amylin as a drug is that it disappears from your bloodstream in about 13 minutes — barely enough time to do anything useful. Novo Nordisk solved that the same way they solved it for their long-acting GLP-1 drugs: attaching a fatty acid to the molecule so it lingers in the blood, while also borrowing structural tricks from salmon calcitonin (a related peptide that binds tightly to the same receptor family). The result is a version of amylin signaling that works on a once-weekly injection instead of requiring multiple daily shots, the way the older amylin drug pramlintide does.
How Is It Different From Semaglutide and Friends?
This is the whole point, so it’s worth being precise. Cagrilintide activates amylin receptors — a receptor complex built from the calcitonin receptor paired with a few accessory proteins. That’s a genuinely separate system from the GLP-1 receptor that semaglutide and tirzepatide’s GLP-1 side act on. Different lock, different key.
In practice, amylin receptor activation in the hypothalamus amplifies your brain’s “I’m full” signal, and receptors in the brainstem seem to play a role too. But here’s the part that’s gotten people excited: cagrilintide appears to specifically dial down what’s often called “food noise” — the intrusive, hard-to-ignore thoughts about food that a lot of people describe as the most exhausting part of managing appetite. That’s distinct from just feeling physically full after a meal. It’s the difference between “I’m not hungry right now” and “I’m not constantly thinking about eating,” and GLP-1 drugs alone don’t seem to touch the second one nearly as well.
Worth being honest about the evidence level on that specific point: “less food noise” is a pattern that’s shown up repeatedly in trial commentary and patient reports, not a formally validated, precisely measured endpoint with its own dedicated scale. It’s a real and consistent observation. It’s not yet a rigorously quantified one.
What Do the Trials Actually Show?
Cagrilintide has moved through a genuinely serious trial program — Phase 2 alone, then large Phase 3 combination trials — and the numbers at each stage are worth looking at separately rather than blurring together.
On its own (Phase 2): In a trial of 706 adults with obesity and no diabetes, cagrilintide 2.4 mg by itself produced about 10.8% weight loss over 26 weeks, versus roughly 3.0% for placebo. Decent, on its own.
Combined with semaglutide — REDEFINE 1: This is where things get interesting. The Phase 3 trial enrolled 3,417 adults with obesity or overweight plus at least one weight-related health issue, no diabetes, over 68 weeks. People got CagriSema (both drugs together), cagrilintide alone, semaglutide alone, or placebo. The combination came out ahead of either drug by itself, landing somewhere in the 20–23% weight-loss range depending on which analysis you look at — with more than half of participants (53.6% to 60%) losing 20% or more of their body weight. Investigators presenting this data have compared that magnitude to what you’d typically expect from bariatric surgery, which is a striking thing to say about an injection. By the end of the trial, over half of the CagriSema group no longer met the clinical definition of having obesity at all.
Combined with semaglutide, in people with diabetes — REDEFINE 2: A companion trial in 1,206 people with overweight or obesity plus type 2 diabetes found that 73.5% of the CagriSema group hit an HbA1c of 6.5% or lower, compared to just 15.9% on placebo — a blood-sugar-control result that matters specifically for this population, separate from the headline weight numbers.
The study that started it all: Before any of this, a smaller Phase 2 trial (Frias et al., The Lancet, 2023) enrolled 92 people with type 2 diabetes and gave the first real human evidence that hitting the amylin and GLP-1 pathways together produces something more than either one alone — genuinely additive, not just overlapping. That finding is exactly what convinced Novo Nordisk to develop CagriSema as a fixed combination rather than trying to sell cagrilintide on its own.
How Does It Stack Up Against Pramlintide, the Older Amylin Drug?
Amylin drugs aren’t new — pramlintide’s been around for years as a diabetes add-on treatment. But pramlintide’s short half-life means multiple injections a day, which is a genuinely hard regimen to stick to and, frankly, a hard trial to run at scale. Cagrilintide’s whole innovation is turning that into once a week, matching the convenience that’s made long-acting GLP-1 drugs so widely adopted. That single change is also what made trials like REDEFINE 1 and 2 practically possible — nobody’s running a multi-year, multi-thousand-person trial on a drug that requires four daily injections.
What’s Its Legal Status Right Now?
Straightforward answer: not approved. Neither cagrilintide alone nor CagriSema has FDA approval as of the most recent published data. Novo Nordisk’s whole regulatory strategy is built around CagriSema as a single combined product, riding on the REDEFINE data — which means cagrilintide currently exists as a clinical-trial compound, not something you can walk into a pharmacy and get. That could change once review wraps up, but it hasn’t yet.
This is worth flagging because cagrilintide’s presence in online discussion has clearly outpaced its actual regulatory status — a pattern that shows up across a lot of unapproved, pre-approval compounds in this space. Our general peptide safety overview covers that broader gap in more depth.
Any Safety Concerns So Far?
Across both the standalone and combination trials, cagrilintide’s side effects have skewed mild-to-moderate and gastrointestinal — nausea, that sort of thing — which lines up with what’s already known about GLP-1 drugs, since both classes slow down digestion in similar ways. As with anything still working through its trial program, the safety picture reflects the population and duration actually studied (68 weeks in REDEFINE), not decades of real-world use. That’s true of every drug at this stage, not a red flag specific to cagrilintide.
Where Cagrilintide Fits in the Bigger Picture
It helps to see where cagrilintide sits next to everything else in this category. Semaglutide and tirzepatide both work by activating GLP-1 receptors (tirzepatide also hits GIP receptors on top of that). Retatrutide goes a step further, adding glucagon receptor activity as a third mechanism layered onto GLP-1 and GIP. Cagrilintide is the only one on this list that skips the GLP-1 receptor entirely — it works through amylin receptors instead. That’s precisely why pairing it with a GLP-1 drug produces something more than either one alone, rather than two drugs competing for the same target and mostly just adding side effects — the same complementary-pathway logic behind most well-designed peptide combinations.
Quick Questions
Is cagrilintide the same thing as CagriSema?
No — cagrilintide is the compound itself; CagriSema is the fixed-dose combination pairing it with semaglutide. Cagrilintide has also been tested alone, but the combination is where the bigger numbers show up.
Can I get cagrilintide without semaglutide?
It’s been studied solo in Phase 2, but Novo Nordisk’s actual path to market is built around the combination — so if it gets approved, it’ll most likely arrive as CagriSema, not as a standalone product.
Is it available anywhere right now?
No. Both cagrilintide and CagriSema are still inside the clinical trial and regulatory review process.
Does cagrilintide cause the same nausea GLP-1 drugs are known for?
Trial data so far shows a similar mild-to-moderate gastrointestinal side effect pattern to GLP-1 drugs, which makes sense given the overlapping effect on digestion — but this isn’t a completely separate side-effect profile, it’s a related one.
Bottom Line
Cagrilintide isn’t just another GLP-1 drug wearing a different name — it works through a genuinely separate hormonal pathway, and its combination with semaglutide has actually been tested in large, controlled, published Phase 3 trials rather than resting on animal data and a good theory. The results so far are substantial, by any standard for a weight-management drug. What’s still missing is regulatory approval itself and longer-term safety data beyond the current trial window — which, again, is true of any drug still working its way through the pipeline.
This is educational content based on published clinical trial data and is not medical advice. Cagrilintide and CagriSema are not currently FDA-approved for use outside clinical trials; nothing in this article should be read as a recommendation for personal use.